Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00669877
Other study ID # ID02-229
Secondary ID NCI-2010-01455
Status Completed
Phase Phase 2
First received
Last updated
Start date August 2002
Est. completion date October 2015

Study information

Verified date April 2018
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small non-cleaved cell B-cell leukemia or lymphoma. Another goal is to see how well this treatment works when given with Rituximab. The safety of the combined treatment will also be studied.


Description:

The hyper-CVAD regimen is a combination of chemotherapy drugs including cyclophosphamide, vincristine, Adriamycin, and dexamethasone given together to for one "course" of treatment. This alternates with a course or combination of the chemotherapy drugs methotrexate and cytarabine. Rituximab is a protein (monoclonal antibody) that attaches to the surface of the leukemia or lymphoma cells which have a marker called cluster of differentiation antigen 20 (CD20).

During treatment, participants will have a physical exam and give blood samples (about 1 tablespoon each) at least twice a week. After two courses of chemotherapy, the tests done before treatment will be repeated to check for response. In patients with leukemia, a bone marrow sample will be repeated 2 and 3 weeks from the beginning of treatment to check the response.

All participants in this study will receive 2 kinds of chemotherapy courses for a total of 8 courses. Chemotherapy courses will be given through a large vein by a central venous catheter (a plastic tube usually placed under the collarbone).

In Course 1 (odd course), participants will receive rituximab by vein over 6 hours on Days 1 and 11. Participants will receive the drugs acetaminophen (Tylenol) and diphenhydramine hydrochloride (Benadryl) 30-60 minutes before each dose of rituximab. This will be done to lessen the risk of fever, chills, and allergic reactions. Usually, the first dose of rituximab requires about 6 hours to complete.

Participants will then receive cyclophosphamide by vein over 2-3 hours every 12 hours for a total of 6 doses, given over 3 days (Days 1, 2, and 3). Adriamycin will be given by vein over 24 hours on Day 4. Vincristine will be given by vein over 15 to 30 minutes on Days 4 and 11 along with dexamethasone by mouth or by vein on Days 1-4 and 11-14.

Participants will also receive pegfilgrastim or G-CSF (growth stimulating colony factor) to help with rapid recovery of the normal bone marrow starting after each course of chemotherapy is finished. Pegfilgrastim is injected under the skin within 72 hours of completion of each cycle of chemotherapy. G-CSF is given by injections by vein or under the skin until the blood counts recover.

Treatment to the brain will be given inside the spinal fluid with cytarabine and methotrexate about Days 2 and 7 of the course to help prevent the leukemia from developing there.

For patients 60 years or older, the first course will be given in a protective isolation room to decrease the risk of infection(s).

In Course 2 (even course), participants will receive rituximab by infusion over about 4 hours on Days 1 and 8. They will receive methotrexate by infusion over 24 hours on the first day, and cytarabine in a high dose over 2 hours every 12 hours for 4 doses (Days 2 and 3). Citrovorum factor (leucovorin) will be given by vein or by mouth for 2-3 days (Day 2 and on) to decrease the risk of side effects of methotrexate. G-CSF will be given as in Course 1 (after the chemotherapy is finished). The treatment to the brain inside the spinal fluid will be given as in course 1 on days 2 and 7.

After two courses of therapy, the response to the treatment will be checked. If the leukemia or lymphoma is responding, the therapy will be continued for a total of 8 courses over 6 months. Therapy will be stopped if the leukemia or lymphoma starts to get worse.

An Ommaya reservoir may also be placed surgically as a route to treat leukemia in the brain or to decrease the risk of leukemia in patients who have difficulty with the spinal treatments. An Ommaya reservoir is a tube inserted under the skin of the scalp that enters into the spinal fluid cavity of the brain.

This is an investigational study. All drugs in this study are commercially available. Their use together in this study is investigational. About 70 patients or more will take part in this study. All will be enrolled at MD Anderson.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

1. Burkitt's or Burkitt-like leukemia and/or lymphoma, either previously untreated, previously treated (may be in CR or with active disease after 1-2 courses of chemotherapy), or HIV-related.

2. All ages are eligible.

3. Zubrod performance status < 3 (ECOG Scale, Appendix A).

4. Adequate liver function (bilirubin < 3.0 mg/dL, unless considered due to tumor), and renal function (creatinine < 3.0 mg/dL, unless considered due to tumor).

5. Signed informed consent.

Exclusion Criteria:

1) N/A

Study Design


Intervention

Drug:
Rituximab
375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.
Cyclophosphamide
300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).
Doxorubicin
50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
Vincristine
2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)
Dexamethasone
40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)
G-CSF
10 mcg/kg
Cytarabine
100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
Methotrexate
200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.

Locations

Country Name City State
United States The University of Texas M. D. Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Overall Response Rate: Percentage of Participants With Complete Remission (CR) or Partial Remission (PR) Complete Remission (CR) was defined as the presence of 5% or less blasts in the bone marrow, with a granulocyte count =1.0 × 10^9/L, a platelet count =100 × 10^9/L, and no extramedullary disease. Complete recovery except platelets (CRp) was defined as for CR, except for recovery of platelet count to <100 × 10^9/L. Partial remission (PR) was defined as a bone marrow with >5% and <25% blasts with a granulocyte count of =1.0 × 109/L and a platelet count of =100 × 10^9/L. Relapse was defined by recurrence of more than 5% lymphoblasts in the bone marrow aspirate or by the presence of extramedullary disease after achieving CR. After two 21-day courses, response to treatment checked for Complete Remission (CR)
Primary Complete Remission Rate: Percentage of Participants With Complete Remission (CR) Complete Remission (CR) was defined as the presence of 5% or less blasts in the bone marrow, with a granulocyte count =1.0 × 10^9/L, a platelet count =100 × 10^9/L, and no extramedullary disease. Complete recovery except platelets (CRp) was defined as for CR, except for recovery of platelet count to <100 × 10^9/L. Partial remission (PR) was defined as a bone marrow with >5% and <25% blasts with a granulocyte count of =1.0 × 109/L and a platelet count of =100 × 10^9/L. Relapse was defined by recurrence of more than 5% lymphoblasts in the bone marrow aspirate or by the presence of extramedullary disease after achieving CR. After two 21-day courses, response to treatment checked for Complete Remission (CR)
See also
  Status Clinical Trial Phase
Terminated NCT02145039 - Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases N/A
Completed NCT01516593 - Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma Phase 2
Completed NCT01314014 - Imexon for Relapsed Follicular and Aggressive Lymphomas Phase 2
Active, not recruiting NCT02722668 - UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Phase 2
Completed NCT02661035 - Allo HSCT Using RIC for Hematological Diseases Phase 2
Completed NCT02669017 - Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) Phase 1
Completed NCT00412243 - Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients Phase 1/Phase 2
Completed NCT01597778 - Double Cord Versus Haploidentical (BMT CTN 1101) Phase 3
Active, not recruiting NCT04464200 - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers Phase 1
Completed NCT00949741 - Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients N/A
Completed NCT00199082 - Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults Phase 4
Completed NCT01474681 - Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Phase 1/Phase 2
Withdrawn NCT01163201 - T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies Phase 1/Phase 2
Completed NCT01859819 - Treatment for Advanced B-Cell Lymphoma Phase 2
Terminated NCT00776373 - Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies Phase 1/Phase 2
Completed NCT01809600 - Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults N/A
Completed NCT00807495 - Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT01962636 - Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases N/A
Completed NCT01397825 - MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine Phase 1/Phase 2
Completed NCT00388193 - Rituximab Combined With Chemotherapy in Burkitt`s Lymphoma Phase 2